Clinical improvement in Job syndrome following administration of co-trimoxazole, omalizumab and inhaled tobramycin.

Abstract

Established treatment regimens for the autosomal dominant hyperimmunoglobulin E syndrome, denominated Job syndrome, are lacking. Thus, Job syndrome still exerts a dramatic impact on patients' quality of life. Our aim was to present safety and effectiveness of a regimen including co-trimoxazole, omalizumab and inhaled tobramycin in Job syndrome. A 26-year-old woman diagnosed with Job syndrome since infancy through sequencing revealing G342D mutation in STAT3 gene was initiated in the above mentioned treatment regimen; she was followed for 6 months, and to date, none recurrent pulmonary or skin infection was noticed. Furthermore, a considerable improvement in skin lesions was observed. A combination of anti-IgE and longitudinal use of inhaled antibiotics seems well-founded in Job syndrome.

• Authors: Ourania Papaioannou, Theodoros Karampitsakos, Matthaios Katsaras, Fotios Sampsonas, Argyrios Tzouvelekis
• Journal: Advances in respiratory medicine (Adv Respir Med) (Oct 20 2021) ISSN: 2543-6031 [Electronic] Switzerland
• PMID: 34668182 (Publication Type: Journal Article)